Repligen’s deal for BioLife Solutions indicates shift to manufacturing integration

CryoStorPositive

AI Analysis

Summary

Repligen acquired BioLife Solutions for $1.5 billion, adding CryoStor biopreservation technology to its bioprocessing portfolio. The deal reflects the pharmaceutical industry's shift toward integrated manufacturing for cell and gene therapy supply chains.

Importance:7/10

Sentiment:

0.60

M&Acell and gene therapybioprocessingsupply chain integrationbiopreservation

Related Companies

$INBP

Read the original article

Published by Pharmaceutical Technology on August 13, 2026 10:20 AM

Read Original